Study: Chlorhexidine-Silver Sulfadiazine-Impregnated Venous Catheters Cuts Costs

Using chlorhexidine-silver sulfadiazine-impregnated venous catheters may lead to fewer catheter-related blood stream infections and lower central-venous catheter related costs, according to a study in the American Journal of Infection Control.

Advertisement

Researchers found patients with CHSS-catheters experienced zero CRBSIs per 1,000 patient days, while patients with standard catheters experienced 5.01 CRBSIs per 1,000 patient days.

Additionally, CHSS-catheters were associated with a lower CVC-related cost per day than standard catheters, at $5.21 and $10.03 (converted from Euros), respectively.

Researchers concluded CHSS-catheters led to reduced CRBSIs and lower costs.

More Articles on Infection Control:

Stethoscopes: New Culprit in MRSA Transmission
CDC: New Vancomycin-resistant Strep Strains Have Appeared
To Prevent MRSA, Healthcare Workers Want Clarified Protocols

 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

When nurses help build the AI, adoption follows: Lessons from 3 health systems

Tuesday, July 28
11:00 AM - 12:00 PM CDT

Presenters: Amy McCarthy, DNP, RNC-MNN, NE-BC, CENP, Hippocratic AIBeth Reimschissel, PhD, RN, CNL, Memorial HermannAllison Schlinkert, MSN, RN, NPD-BC, Cincinnati Children'sScott Estep, MBOE, BSN, RN, CSSBB, OhioHealth System

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.